HAEMONETICS CORP (HAE)

Data as of Jul 28, 2026, from SEC Form 4 filings.

XNYSSURGICAL & MEDICAL INSTRUMENTS & APPARATUSNo open-market insider trades (90d)Watch HAE

See up to 3 months of HAE. The 7-day demo opens the 1M and 3M ranges and puts HAE on your watchlist.

Latest HAE insider trades

Mark W. Kroll - Director
Open-market purchase$99K
Nov 10, 2025
Martin D. Madaus - Director
Grant or award2,538 sh
Jul 24, 2026
Ellen M. Zane - Director

About HAEMONETICS CORP (HAE)

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Headquarters: BOSTON, MA
Employees: 3,009
Listed: 1991
Exchange: XNYS
Sector: Health Care

https://www.haemonetics.com SEC filings for HAE on EDGAR

HAE Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Grant or award	8	20,304

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

HAE insider transactions (Form 4)

30 Form 4 filings on record, the earliest from Nov 5, 2024, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Jul 24, 2026	Martin D. Madaus - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Ellen M. Zane - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Claire Pomeroy - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Mark W. Kroll - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Lloyd Emerson Johnson - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Michael J. Coyle - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Diane M. Bryant - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jul 24, 2026	Robert E. Abernathy - Director	Grant or award	Common Stock	2,538^{footnote F1}	-^{footnote F2}	-
Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Jun 5, 2026	Farris Maryanne Maunsell - Officer	Tax withholding / forfeiture	Common Stock	259^{footnote F1}	$71.28	$18K
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Jun 5, 2026	Laurie A. Miller - Officer	Tax withholding / forfeiture	Common Stock	313^{footnote F1}	$71.28	$22K
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
May 15, 2026	Michelle L. Basil - Officer	Tax withholding / forfeiture	Common Stock	2,913^{footnote F1}	$56.29	$164K
May 15, 2026	Michelle L. Basil - Officer	Grant or award	Common Stock	28,424^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	Frank Chan - Officer	Tax withholding / forfeiture	Common Stock	546^{footnote F1}	$56.29	$31K
May 15, 2026	Frank Chan - Officer	Grant or award	Common Stock	27,535^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	James Darecca - Officer	Tax withholding / forfeiture	Common Stock	2,505^{footnote F1}	$56.29	$141K
May 15, 2026	James Darecca - Officer	Grant or award	Common Stock	29,312^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	Farris Maryanne Maunsell - Officer	Tax withholding / forfeiture	Common Stock	197^{footnote F1}	$56.29	$11K
May 15, 2026	Farris Maryanne Maunsell - Officer	Grant or award	Common Stock	2,220^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	Roy Galvin - Officer	Tax withholding / forfeiture	Common Stock	879^{footnote F1}	$56.29	$49K
May 15, 2026	Roy Galvin - Officer	Grant or award	Common Stock	27,535^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	Laurie A. Miller - Officer	Tax withholding / forfeiture	Common Stock	948^{footnote F1}	$56.29	$53K
May 15, 2026	Laurie A. Miller - Officer	Grant or award	Common Stock	13,323^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 15, 2026	Christopher Simon, - Officer	Tax withholding / forfeiture	Common Stock	9,681^{footnote F1}	$56.29	$545K
May 15, 2026	Christopher Simon, - Officer	Grant or award	Common Stock	78,344^{footnote F3}	-^{footnote F4}	-
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
May 1, 2026	James Darecca - Officer	Tax withholding / forfeiture	Common Stock	655^{footnote F1}	$59.26	$39K
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Nov 10, 2025	Mark W. Kroll - Director	Open-market purchase	Common Stock	1,400	$70.56	$99K
Oct 31, 2025	Roy Galvin - Officer	Tax withholding / forfeiture	Common Stock	145^{footnote F1}	$50.01	$7K
Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Sep 17, 2025	Laurie A. Miller - Officer	Tax withholding / forfeiture	Common Stock	238	$49.95	$12K
Jul 24, 2025	Lloyd Emerson Johnson - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Diane M. Bryant - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Claire Pomeroy - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Charles J. Dockendorff - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Ellen M. Zane - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Mark W. Kroll - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Michael J. Coyle - Director	Grant or award	Common Stock	2,693	-	-
Jul 24, 2025	Robert E. Abernathy - Director	Grant or award	Common Stock	2,693	-	-
Nov 1, 2024	Roy Galvin - Officer	Tax withholding / forfeiture	Common Stock	161	$71.48	$12K

Recent HAE Form 8-K filings

Read HAE company news

Oct 8, 2026Item 7.01

Read the filing on SEC EDGAR

Aug 18, 2026Item 7.01

Read the filing on SEC EDGAR

Aug 6, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Jul 28, 2026Item 5.02, 5.07, 9.01

Read the filing on SEC EDGAR

HAE insider trading FAQ

What is the latest insider trade for HAE?

HAEMONETICS CORP (HAE) had 8 insider filings in the last 90 days, with the most recent on 2026-07-28. The full record for HAE runs to 30 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying HAE stock?

No insider purchases of HAE were filed in the last 90 days. 1 purchase is on record for this company.

How many insiders are selling HAE stock?

No insider sales of HAE were filed in the last 90 days.

Where can I see HAE SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects HAE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Jul 28, 2026 - Martin D. Madaus view on EDGAR
Jul 28, 2026 - Ellen M. Zane view on EDGAR
Jul 28, 2026 - Claire Pomeroy view on EDGAR
Jul 28, 2026 - Mark W. Kroll view on EDGAR
Jul 28, 2026 - Lloyd Emerson Johnson view on EDGAR
Jul 28, 2026 - Michael J. Coyle view on EDGAR
Jul 28, 2026 - Diane M. Bryant view on EDGAR
Jul 28, 2026 - Robert E. Abernathy view on EDGAR
Jun 8, 2026 - Farris Maryanne Maunsell view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where HAE's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow HAE with a 7-day demo

HAE on your watchlist
Every HAE Form 4 filing on record
Up to 3 months of HAE price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Grant or award

20,304

Date

Insider

Transaction

Security

Price

Value

Jul 24, 2026

Martin D. Madaus - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Ellen M. Zane - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Claire Pomeroy - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Mark W. Kroll - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Lloyd Emerson Johnson - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Michael J. Coyle - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Diane M. Bryant - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jul 24, 2026

Robert E. Abernathy - Director

Grant or award

Common Stock

2,538^{footnote F1}

-^{footnote F2}

Footnote F1 (shares): The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
Footnote F2 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Jun 5, 2026

Farris Maryanne Maunsell - Officer

Tax withholding / forfeiture

Common Stock

259^{footnote F1}

$71.28

$18K

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

Jun 5, 2026

Laurie A. Miller - Officer

Tax withholding / forfeiture

Common Stock

313^{footnote F1}

$71.28

$22K

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

May 15, 2026

Michelle L. Basil - Officer

Tax withholding / forfeiture

Common Stock

2,913^{footnote F1}

$56.29

$164K

May 15, 2026

Michelle L. Basil - Officer

Grant or award

Common Stock

28,424^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

Frank Chan - Officer

Tax withholding / forfeiture

Common Stock

546^{footnote F1}

$56.29

$31K

May 15, 2026

Frank Chan - Officer

Grant or award

Common Stock

27,535^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

James Darecca - Officer

Tax withholding / forfeiture

Common Stock

2,505^{footnote F1}

$56.29

$141K

May 15, 2026

James Darecca - Officer

Grant or award

Common Stock

29,312^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

Farris Maryanne Maunsell - Officer

Tax withholding / forfeiture

Common Stock

197^{footnote F1}

$56.29

$11K

May 15, 2026

Farris Maryanne Maunsell - Officer

Grant or award

Common Stock

2,220^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

Roy Galvin - Officer

Tax withholding / forfeiture

Common Stock

879^{footnote F1}

$56.29

$49K

May 15, 2026

Roy Galvin - Officer

Grant or award

Common Stock

27,535^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

Laurie A. Miller - Officer

Tax withholding / forfeiture

Common Stock

948^{footnote F1}

$56.29

$53K

May 15, 2026

Laurie A. Miller - Officer

Grant or award

Common Stock

13,323^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 15, 2026

Christopher Simon, - Officer

Tax withholding / forfeiture

Common Stock

9,681^{footnote F1}

$56.29

$545K

May 15, 2026

Christopher Simon, - Officer

Grant or award

Common Stock

78,344^{footnote F3}

-^{footnote F4}

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
Footnote F3 (shares): The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the… Full note on SEC EDGAR
Footnote F4 (price): Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

May 1, 2026

James Darecca - Officer

Tax withholding / forfeiture

Common Stock

655^{footnote F1}

$59.26

$39K

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

Nov 10, 2025

Mark W. Kroll - Director

Open-market purchase

Common Stock

1,400

$70.56

$99K

Oct 31, 2025

Roy Galvin - Officer

Tax withholding / forfeiture

Common Stock

145^{footnote F1}

$50.01

$7K

Footnote F1 (shares): Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

Sep 17, 2025

Laurie A. Miller - Officer

Tax withholding / forfeiture

Common Stock

238

$49.95

$12K

Jul 24, 2025

Lloyd Emerson Johnson - Director

Grant or award

Common Stock

2,693